Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

PR Newswire TEL AVIV, Israel, April 17, 2025 Collaboration to Reverse Drug Resistance in GI Cancers TEL AVIV, Israel, April 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (N ...

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older ...

Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are the standard of care for treating locally advanced or metastatic ...

An estimated 18,000 people in the United States annually suffer from new injuries to their spinal cords. Unfortunately for ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...